anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for treating vegetative dysfunctions of hypotensive type in the children comprises the use of the sedative drugs. The patients are examined beforehand. The presence of cerebrosthenic syndrome is assessed. Cardiointervalography and rheoencephalography are provided. When the altered vegetative reactivity is revealed, Tenoten (dosage form for children) is provided at a dose of one tablet thrice a day. In case of cerebrosthenic syndrome and altered cerebral hemodynamics, Homvionervin is provided a dose of one tablet thrice a day.
Vinflunine 280 mg/m2 every 21 days with trastuzumab administered with a loading dose of 8 mg/kg, followed by 6 mg/kg IV on day 1 of each subsequent cycle, repeated every 21 days. If no grade 3/4 adverse events were encountered after the first cycle of vinflunine/trastuzumab, the dose of vinflunine could be escalated to 320 mg/m2.
<P>PROBLEM TO BE SOLVED: To improve operability and convenience of a medical image system.  <P>SOLUTION: In the medical image system 1, a CPU 11 extracts a patient's disease site to be an object from a plurality of sites corresponding to a designated part in a medical information database when one part on a site designating screen is designated, and displays a listing screen of the disease site on a display part 13. When the disease site is selected on the listing screen of the disease site, the CPU 11 displays the listing screen of a photographing name of a detailed screen regarding the disease site on the part 13. The photographing name photographed with respect to the disease site and a representative image are displayed on the listing screen of the photographing name. When one of the photographing names is selected, the CPU 11 displays the screen according to the photographing name on the part 13, and when an image index is selected on the screen according to the photographing name, the CPU 11 displays the selected medical image on the part 13.  <P>COPYRIGHT: (C)2003,JPO
The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
A male infant, aged 6 days, was admitted to the hospital due to respiratory distress and systemic desquamative rash after birth. The infant presented with erythema and desquamative rash, respiratory failure, recurrent infections, chronic diarrhea, hypernatremic dehydration, and growth retardation. Comprehensive treatment, including anti-infection therapy, intravenous immunoglobulin administration, and skin care, resulted in improvement of the rash, but recurrent infections persisted. Second-generation sequencing revealed a homozygous mutation in the SPINK5 gene, consistent with the pathogenic variation of Netherton syndrome. The family opted for palliative care, and the infant died at the age of 2 months after discharge. This report documents a case of Netherton syndrome caused by the SPINK5 gene mutation in the neonatal period, and highlights multidisciplinary diagnosis and therapy for this condition.
PURPOSE: To obtain a nasal medicine containing a medicine detoxicating the neurotoxin having acetylcholinesterase inhibiting action, capable of quickly manifesting the effect of a medicine against neurotoxin with a simple operation and useful as a new nasal antidote. CONSTITUTION: This antidote contains a medicine detoxicating a neurotoxin having acetylcholinesterase inhibiting action. As the neurotoxin, e.g. an organic phosphorus-based pesticide such as parathion or malation and/or a neurergic gas organic phosphorus compound such as sarin or VX is exemplified. As the medicine detoxicating these neurotoxins, e.g. 2-pyridine aldoxime methyl chloride or atropine is exemplified. An using amount of the medicine is preferably the same amount-20 times amount of the case of injection administration and the same amount or lower than the case of oral administration. The objective nasal medicine can be administrated into nasal cavity in the form of a quantitative propellant by dispersing it in a spray such as CFC and filling the dispersion in a pressure vessel.
This single-center, single-arm, open-label trial will include 89 patients with stage II-III triple-positive breast cancer (Simon's two-stage design). After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
FIELD: medicine, peptides, pharmacy. SUBSTANCE: invention proposes biologically active tetrapeptide lysyl-glutamyl-aspartyl-alanine of the general formula: Lys-Glu-Asp-Ala stimulating functional activity of hepatocytes and pharmacological agent containing effective amount of tetra-peptide of the formula Lys-Glu-Asp-Ala or its salts as an active component that can be used for parenteral, intranasal and oral administration. Method of stimulation of functional activity of hepatocytes involves curative administration to patient the pharmacological agent in doses 0.01-100 mcg/kg of body mass for at least once per a day for period that is necessary for therapeutic effect attainment. Agent stimulating functional activity of hepatocytes recoveries synthesis of nonspecific proteins, normalizes metabolism, activates processes of proliferation and differentiation of liver cells. Invention can be used as an agent stimulating functional activity of hepatocytes for prophylaxis and treatment of patients with diseases and damages of liver. EFFECT: enhanced effectiveness of agent, improved method of use. 10 cl, 3 dwg, 5 tbl, 7 ex
The present application provides a proteolysis targeting influenza virus, a method for preparing same and use thereof. The proteolysis targeting influenza virus comprises a hydrolysis targeting M1 protein, and the hydrolysis targeting M1 protein comprises a TEVp recognition site and a protein hydrolysis targeting molecule recognized by the ubiquitin-proteasome system which are sequentially inserted into the C-terminus. The protein hydrolysis targeting molecule recognized by the ubiquitin-proteasome system comprises the amino acid sequences set forth in SEQ ID Nos. 1-353. The hydrolysis targeting M1 protein can be recognized by the ubiquitin-proteasome system and thus hydrolyzed, such that the replicative capacity of the virus is reduced; therefore, the safety of the virus is relatively high. The proteolysis targeting influenza virus provided by the present application has many subtypes, which play an important role in the research and development of vaccines against influenza viruses.
OBJECTIVE: To investigate the association between blood calcium concentration and incident kidney stone as well as to assess the role played by genetic susceptibility.
METHODS: We performed a population-based cohort study based on participants from the UK Biobank. A multivariable Cox proportional hazards regression model was used to estimate hazard ratios (HRs) and 95% CIs of incident kidney stone for blood calcium level and polygenic risk score (PRS). In addition, the potential interaction was explored. The study was conducted from January 28, 2023, through June 4, 2023.
RESULTS: During the follow-up of 423,301 participants with a total of 5,490,332 person-years (median follow-up of 13.4 years), 4502 cases of kidney stone were recorded. Compared with the low blood calcium concentration group (first tertile), individuals in the high (third tertile) and moderate (second tertile) concentration groups had higher risks of kidney stone with HRs of 1.24 (95% CI, 1.15 to 1.33) and 1.11 (1.04 to 1.20), respectively. The PRS for kidney stone contained 40 independent single-nucleotide polymorphisms and was used to assign individuals to 3 groups according to the quintile. Participants with high (Q5) and moderate (Q2 to Q4) genetic risks had increased risks of kidney stone compared with low (Q1) genetic risk with HRs of 1.70 (1.53 to 1.89) and 1.31 (1.20 to 1.44), respectively. There was a joint cumulative risk of incident kidney stone between blood calcium concentration and genetic susceptibility.
CONCLUSIONS: Blood calcium concentration and PRS are significantly associated with incident kidney stone risk. Excessive blood calcium concentration might bring additional stone risk in populations at high genetic risk. A nonlinear correlation between blood calcium concentration and kidney stone risk was indicated.
OBJECTIVE: Enhanced recovery after surgery (ERAS) guidelines have been successfully applied to children and neonates. There is a need to provide evidence-based consensus recommendations to manage neonatal pain perioperatively to ensure adequate analgesia while minimising harmful side effects.
METHODS: Following a stakeholder needs assessment, an international guideline development committee (GDC) was established. A modified Delphi consensus iteratively defined the scope of patient and procedure inclusion, topic selection and recommendation content regarding the pharmacologic management of neonatal pain. Critical appraisal tools assessed the relevance and quality of full-text studies. Each recommendation underwent a formal Grades of Recommendation, Assessment, Development and Evaluation (GRADE) assessment of the quality of evidence and expert consensus was used to determine the strength of recommendations.
RESULTS: The GDC included paediatric anaesthesiologists, surgeons, and ERAS methodology experts. The population was defined as neonates at >32 weeks gestational age within 30 days of life undergoing surgery or painful procedures associated with surgery. Topic selection targeted pharmacologic opioid-minimising strategies. A total of 4249 abstracts were screened for non-opioid analgesia and 738 abstracts for the use of locoregional analgesia. Full-text review of 18 and 9 articles, respectively, resulted in two final recommendations with a moderate quality of evidence to use regular acetaminophen and to consider the use of locoregional analgesia. There was inadequate evidence to guide the use of other non-opioid adjuncts in this population.
CONCLUSIONS: Evidence-based, ERAS-driven consensus recommendations were developed to minimise opioid usage in neonates. Further research is required in this population to optimize multimodal strategies for pain control.
Patients with underlying hepatitis B or C or marked elevations in transaminase prior to treatment may be at increased risk for developing or worsening of transaminase elevations or hepatic decompensation with use of KALETRA.

There have been postmarketing reports of hepatic dysfunction, including some fatalities. These have generally occurred in patients with advanced HIV-1 disease taking multiple concomitant medications in the setting of underlying chronic hepatitis or cirrhosis. A causal relationship with KALETRA therapy has not been established. 

Elevated transaminases with or without elevated bilirubin levels have been reported in HIV-1 mono-infected and uninfected patients as early as 7 days after the initiation of KALETRA in conjunction with other antiretroviral agents. In some cases, the hepatic dysfunction was serious; however, a definitive causal relationship with KALETRA therapy has not been established. 

Appropriate laboratory testing should be conducted prior to initiating therapy with KALETRA and patients should be monitored closely during treatment. Increased AST/ALT monitoring should be considered in the patients with underlying chronic hepatitis or cirrhosis, especially during the first several months of KALETRA treatment [see Use In Specific Populations (8.6)].
Disclosed herein is a preservative formulation for skin care products, comprising constituents including: a) glyceryl laurate present in a concentration from about 55wt./wt. % to about 90 wt./wt.% of the formulation b) at least one alcohol selected from the group consisting of nerolidol, phenyl hexanol, and any combination thereof present in a concentration from about 3 to about 30 wt./wt. %, wherein if present, nerolidol is present in a concentration of up to about 11wt./wt. %, and if present, phenyl hexanol is present in a concentration of up to about 30 wt./wt. % of the formulation; and c) at least one chelating agent present in a concentration from about 0.1 to about 20 wt./wt. % of the formulation.
PURPOSE: To obtain an oral hygienic product in the form of a liquid intraoral detergent compsn. consisting of a granular drug stably suspended in a liquid intoraoral detergent compsn. CONSTITUTION: A single system is obtd. by stably suspending a granular drug is liquid medium containing a specified polymer having <=1×10<6> average mol.wt. selected from a group of protein polymers, polysaccharide polymers, copolymers of vinylpyrolidone and acryl monomers and mixture of them. As for the polymer, for example, gelatin and polymer JR can be used, and as for the proper granular drug, magnesium fluoride is used.
Alongside the recognized potential negative repercussions of working as a psychological therapist, there is growing interest in the potential positive impacts of engaging in such work. The current study used a cross-sectional online survey design to explore the impact of a range of demographic, work-related, and compassion-related factors on levels of secondary traumatic stress (STS) and vicarious posttraumatic growth (VPTG) in an international sample of 359 psychological therapists. Hierarchical multiple regressions demonstrated that burnout, lower levels of self-compassion, having a personal trauma history, reporting a higher percentage of working time with a trauma focus, and being female were the statistically significant contributors to STS scores, explaining 40.8% of the variance, F(9, 304) = 23.2, p <.001. For VPTG, higher compassion satisfaction, higher self-compassion, higher STS, a higher percentage of working time with a trauma focus, fewer years qualified, being male, and having a personal trauma history were all statistically significant contributors, explaining 27.3% of the variance, F (10, 304) = 11.37, p <.001. The findings illustrate the potential risk and protective factors for developing STS and clarify factors that may increase the likelihood of experiencing VPTG. Implications for psychological therapists and the organizations and institutions for which they work are considered along with potential directions for future research in the discussion.
The invention relates to the field of traditional Chinese medicine formulas and provides medicinal liquor for treating toothache. The medicinal liquor for treating toothache is prepared by using the following raw materials in parts by weight: 15-25 parts of unprocessed kusnezoff monkshood root, 4-10 parts of pricklyash peel, 4-8 parts of camphor, 5-15 parts of Manchurian wildginger, 3-7 parts of ginger, 5-10 parts of honeysuckle bud and flower, 20-25 parts of dahurian angelica root, 15-20 parts of paniculate swallowwort root, 5-10 parts of Phryma leptostachya, 4-8 parts of rosin, 5-10 parts of liquorice root and 4-6 parts of borneol. The amount of used high-alcohol liquor is determined based on a standard that the medicinal raw materials can be immersed by the used high-alcohol liquor. The invention further provides a preparation method of the medicinal liquor for treating toothache. The preparation method comprises the steps of firstly grinding the medicinal raw materials into powder, submerging the powder in the high-alcohol liquor to an extent that the medicinal raw materials are immersed by the high-alcohol liquor, placing the liquor for five minutes, igniting the medicinal liquor, and cooling the liquor to room temperature after the medicinal liquor is naturally flamed out. The medicinal liquor has a remarkable curative effect for treating toothache and takes effect quickly.
PROBLEM TO BE SOLVED: To obtain a new lipase inhibitor by using a specific triterpene compound and its derivative as active ingredients and further to obtain cosmetics, pet foods and foods which are excellent in lipase inhibitory activity and high in safety by formulating this inhibitor thereto. SOLUTION: These cosmetic, pet food and food contain at least one kind selected from the group consisting of a compound of formula I or II [R<1> is OH and O-C(O)-CH3 ; R<2> to R<4> are each H, CH3 , CH2 OH, etc.; R<5> to R<8> are each H and CH3 ; R<9> is OH and the like; R<10> to R<12> are each H, CH3 , etc.] and its derivative as active ingredients. As the lipase inhibitor, the compound of formula II and its derivative are particularly preferable. By formulating this lipase inhibitor with cosmetic materials, pet foods and foods, skin eruptions, pimples and skin roughening can be continuously suppressed and further the inhibitor can be utilized for preventing foods containing oils and fats from deterioration. Furthermore, the calorie of foods and feeds can be decreased and in addition adult diseases are effectively prevented.
Usual care with loop-diuretics as the sole diuretic (SGLT2-inhibitors allowed) including guideline-recommended increase in loop-diuretic dose and fluid and salt-restriction. This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).
PURPOSE:To provide a hair-treatment agent composition containing a silicone modified with a cyclic Bunte salt and a reducing agent and effective in imparting hair with split-prevention effect and luster durable over a long period. CONSTITUTION:The objective composition contains 0.01-50wt.% of a cyclic Bunte salt-modified silicone of formula I (X is alkali metal, alkaline-earth metal, ammonia, amine or quaternary ammonium salt; n is 4-10; m is 3-11) and 0.1-20wt.% of a reducing agent (e.g. thioglycolic acid). More desirably, the composition is produced by compounding 0.1-50wt.% of compounds of formula II and formula III (R is H, 1-4C alkyl, etc.; Y is H or OH; p, q and r are 0-5; R3 is 8-18C alkyl) and properly compounding conventional components for hair- treatment. The composition is used in the form of two-pack type composition consisting of the 1st agent containing the compound of formula I and the 2nd agent containing the reducing agent.
BACKGROUND: KIAA1429, a regulatory subunit of the N6-methyladenosine (m6A) methyltransferase complex, has been implicated in the progression of various cancers. However, the role of KIAA1429 in gastric cancer (GC) and its underlying mechanisms remain elusive. This study aimed to investigate the role of KIAA1429 in GC and to elucidate the underlying mechanisms.
METHODS: The expression patterns and clinical relevance of KIAA1429 in GC were assessed using quantitative real-time PCR (qRT-PCR), Western blotting, immunohistochemistry (IHC), and bioinformatic analysis. In vitro and in vivo loss- and gain-of-function assays, m6A dot blot assays, methylated RNA immunoprecipitation sequencing (MeRIP-seq), RNA-seq, MeRIP-qPCR, dual luciferase reporter assays, RNA stability assays, RNA immunoprecipitation (RIP) assays, and RNA pull-down assays were performed to investigate the biological functions and underlying molecular mechanisms of KIAA1429 in GC.
RESULTS: Both the mRNA and protein expression of KIAA1429 were greater in GC tissues than in normal gastric tissues. High KIAA1429 expression correlated positively with poor prognosis in GC patients. KIAA1429 not only promoted GC cell proliferation, colony formation, G2/M cell cycle transition, migration, and invasion in vitro but also enhanced GC tumor growth and metastasis in vivo. Mechanistically, KIAA1429 increased the m6A level of RASD1 mRNA and enhanced its stability in an m6A-YTHDF2-dependent manner, thereby upregulating its expression. RASD1 knockdown partially rescued the KIAA1429 knockdown-induced impairment of pro‑oncogenic ability in GC cells. The expression levels of KIAA1429 and RASD1 were negatively correlated in GC tissues.
CONCLUSIONS: KIAA1429 plays a pro‑oncogenic role in GC by downregulating RASD1 expression through destabilizing RASD1 mRNA in an m6A-YTHDF2-dependent manner. KIAA1429 may serve as a prognostic biomarker and therapeutic target for GC.
Prothymosin α (ProT), a highly acidic nuclear protein with multiple cellular functions, has shown potential neuroprotective properties attributed to its anti‑necrotic and anti‑apoptotic activities. The present study aimed to investigate the beneficial effect of ProT on neuroplasticity after ischemia‑reperfusion injury and elucidate its underlying mechanism of action. Primary cortical neurons were either treated with ProT or overexpressing ProT by gene transfection and exposed to oxygen‑glucose deprivation for 2 h in vitro. Immunofluorescence staining for ProT and MAP‑2 was performed to quantify ProT protein expression and assess neuronal arborization. Mice treated with vehicle or ProT (100 µg/kg) and ProT overexpression in transgenic mice received middle cerebral artery occlusion for 50 min to evaluate the effect of ProT on neuroplasticity‑associated protein following ischemia‑reperfusion injury. The results demonstrated that in cultured neurons ProT significantly increased neurite lengths and the number of branches, accompanied by an upregulation mRNA level of brain‑derived neurotrophic factor. Furthermore, ProT administration improved the protein expressions of synaptosomal‑associated protein, 25 kDa and postsynaptic density protein 95 after ischemic‑reperfusion injury in vivo. These findings suggested that ProT can potentially induce neuroplasticity effects following ischemia‑reperfusion injury.
AM001 Cream, 7.5%. 2x daily for 12 weeks.
Glioblastoma (GBM) is the most common and aggressive primary brain cancer; angiogenesis and immunosuppression exacerbate GBM progression. COUP-TFII demonstrates pro-angiogenesis activity; however, its role in glioma progression remains unclear. This study revealed that COUP-TFII promotes angiogenesis in gliomas by inducing transdifferentiation of glioma cells into endothelial-like cells. Mechanistic investigation suggested that COUP-TFII as a transcription factor exerts its function via binding to the promoter of TXNIP. Interestingly, COUP-TFII knockdown attenuated tumorigenesis and tumor progression in an immunocompetent mouse model but promoted tumor progression in an immuno-deficient mouse model. As an explanation, repression of COUP-TFII induces cellular senescence and activates immune surveillance in glioma cells in vitro and in vivo. In addition, we used heparin-polyethyleneimine (HPEI) nanoparticles to deliver COUP-TFII shRNA, which regulated tumor angiogenesis and immunosuppression in an in situ GBM mouse model. This study provides a novel strategy and potential therapeutic targets to treat GBM.